Regeneron Fundamentals

REGN
 Stock
  

USD 628.71  4.81  0.77%   

Regeneron Pharmaceuticals fundamentals help investors to digest information that contributes to Regeneron Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Regeneron Stock. The fundamental analysis module provides a way to measure Regeneron Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regeneron Pharmaceuticals stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Regeneron Pharmaceuticals Interest Expense is quite stable at the moment as compared to the past year. The company's current value of Interest Expense is estimated at 6.65 Million. Net Income is expected to rise to about 8.7 B this year, although the value of Weighted Average Shares will most likely fall to about 98.1 M.

Regeneron Earnings Per Share Analysis

Regeneron Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
 2015 2016 2021 2022 (projected)
Enterprise Value56.23 B38.18 B34.36 B37.07 B
Average Equity3.32 B4.2 B3.78 B4.07 B
Earnings per Share 
 = 
Earnings 
Average Shares 
More About Earnings Per Share | All Equity Analysis

Current Regeneron Pharmaceuticals Earnings Per Share

    
  62.53 X  
Most of Regeneron Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regeneron Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Regeneron Earnings Per Share Historical Pattern

Today, most investors in Regeneron Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Regeneron Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's earnings per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Regeneron Pharmaceuticals earnings per share as a starting point in their analysis.
   Regeneron Pharmaceuticals Earnings Per Share   
Share
       Timeline  
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Compare to competition

Regeneron Shareholders Equity

Shareholders Equity

20.25 Billion

Regeneron Pharmaceuticals Shareholders Equity is quite stable at the moment as compared to the past year. The company's current value of Shareholders Equity is estimated at 20.25 Billion
According to the company disclosure, Regeneron Pharmaceuticals has an Earnings Per Share of 62 times. This is much higher than that of the Healthcare sector and notably lower than that of the Biotechnology industry. The earnings per share for all United States stocks is notably lower than that of the firm.

Regeneron Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Regeneron Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Regeneron Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regeneron Pharmaceuticals competition to find correlations between indicators driving Regeneron Pharmaceuticals's intrinsic value. More Info.
Regeneron Pharmaceuticals is currently regarded as top stock in shares owned by insiders category among related companies. It is currently regarded as top stock in operating margin category among related companies reporting about  21.20  of Operating Margin per Shares Owned by Insiders. Regeneron Pharmaceuticals Operating Margin is quite stable at the moment as compared to the past year. The company's current value of Operating Margin is estimated at 60.06. Comparative valuation analysis is a catch-all model that can be used if you cannot value Regeneron Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Regeneron Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Regeneron Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Regeneron Retained Earnings Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regeneron Pharmaceuticals' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regeneron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Regeneron Pharmaceuticals by comparing valuation metrics of similar companies.
Regeneron Pharmaceuticals is currently under evaluation in retained earnings category among related companies.

Regeneron Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Regeneron Pharmaceuticals from analyzing Regeneron Pharmaceuticals' financial statements. These drivers represent accounts that assess Regeneron Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Regeneron Pharmaceuticals' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee193.31 K330.32 K261.21 K384.04 K778.87 K840.36 K
Revenue Per Employee947.13 K906.87 K970.79 K928.85 K1.55 M1.67 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA2.25 B2.73 B2.66 B4.1 B9.66 B10.43 B

Regeneron Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Regeneron Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Regeneron Pharmaceuticals' managers, analysts, and investors.
Environment Score
Governance Score
Social Score

Regeneron Fundamentals

About Regeneron Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Regeneron Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regeneron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regeneron Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue956.2 MB
Cost of Revenue269.7 M291 M
Revenues16.1 B17.3 B
Revenue to Assets 0.63  0.59 
Revenue Per Employee1.6 M1.7 M
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10492 people.

Regeneron Pharmaceuticals Investors Sentiment

The influence of Regeneron Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Regeneron. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Regeneron Pharmaceuticals' public news can be used to forecast risks associated with investment in Regeneron. The trend in average sentiment can be used to explain how an investor holding Regeneron can time the market purely based on public headlines and social activities around Regeneron Pharmaceuticals. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Regeneron Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Regeneron Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Regeneron Pharmaceuticals' news discussions. The higher the estimate score, the more favorable is the investor's outlook on Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Implied Volatility

    
  30.18  
Regeneron Pharmaceuticals' implied volatility exposes the market's sentiment of Regeneron Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Regeneron Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Regeneron Pharmaceuticals stock will not fluctuate a lot when Regeneron Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regeneron Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regeneron Pharmaceuticals' short interest history, or implied volatility extrapolated from Regeneron Pharmaceuticals options trading.

Currently Active Assets on Macroaxis

Additionally, take a look at Regeneron Pharmaceuticals Piotroski F Score and Regeneron Pharmaceuticals Altman Z Score analysis. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.73
Market Capitalization
68.3 B
Quarterly Revenue Growth YOY
-0.44
Return On Assets
0.18
Return On Equity
0.32
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.